Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study
Authors:
- Sara ZuzziSZSara Zuzzi
- Micaela RanieriMRMicaela Ranieri
- Carmelina PetruzzielloCPCarmelina Petruzziello
- Emma CalabreseECEmma Calabrese
- Sara OnaliSOSara Onali
- Marta AscolaniMAMarta Ascolani
- Francesca ZorziFZFrancesca Zorzi
- Giovanna CondinoGCGiovanna Condino
- Simona IacobelliSISimona Iacobelli
- Francesco PalloneFPFrancesco Pallone
- 1 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 6 (5) , 578-587
Abstract
The combined role of immunomodulators (IMM) and clinical characteristics of Inflammatory Bowel Disease (IBD) in determining the cancer risk is undefined. The aim was to assess whether clinical characteristics of IBD are independent risk factors for cancer, when considering thiopurines and anti-TNFs use. In a single-center cohort study, clinical characteristics of IBD patients with IBD duration ≥1 year and ≥2 visits from 2000 to 2009 were considered. Tests for crude rates and survival analysis methods were used to assess differences of incidence of cancer between groups. The methods were adjusted for the time interval between diagnosis and immunomodulatory treatments. IBD population included 1222 patients :615 Crohn's disease (CD), 607 ulcerative colitis (UC). Cancer was diagnosed in 51 patients (34 CD,17 UC), with an incidence rate of 4.3/1000 pt/year. The incidence rate of cancer was comparable between CD and UC (4.6/1000 pt/year vs 2.9/1000 pt/year ;p=n.s.). Cancer most frequently involved the breast, the GI tract, the skin. Lymphoma was diagnosed in CD (1HL, 1NHL,0 HSTCL). Risk factors for cancer included older age at diagnosis of IBD (CD: HR 1.25;95%CI 1.08-1.45; UC:HR 1.33;95%CI 1.15-1.55 for an increase by 5 years; p=0.0023; p=0.0002), fistulizing pattern in CD (HR 2.55; 95%CI 1.11-5.86,p=0.0275), pancolitis in UC (HR 2.79;95%CI 1.05-7.40 p=0.0396 vs distal). IMM and anti-TNFs did not increase the cancer risk in CD, neither IMM in UC (anti-TNFs risk in UC not feasible as no cases observed). Fistulizing pattern in CD, pancolitis in UC and older age at diagnosis of IBD are independent risk factors for cancer.Keywords
This publication has 47 references indexed in Scilit:
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort studyThe Lancet, 2009
- Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurineGut, 2005
- Epstein-Barr virus–positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurineGastroenterology, 2002
- Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is lowGut, 2000
- Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphomaGastroenterology, 2000
- Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurineThe Lancet, 1996
- Long-term neoplasia risk after azathioprine treatment in inflammatory bowel diseaseThe Lancet, 1994
- Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic TrialBMJ, 1974
- AZATHIOPRINE FOR CROHN'S DISEASEThe Lancet, 1969